LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

UniQure stock crashed Monday on "confusing" and "unexpected" feedback from the FDA for its Huntington's disease gene therapy.

A study found 26 DNA regions tied to fibromyalgia, showing the disorder originates in the brain’s pain circuits, not in muscles.

uniQure called the feedback "unexpected" and "a drastic change" from guidance provided by the FDA in November 2024, when the agency indicated that data from ongoing studies compared to natural history ...

On Monday, Marshall University hosted its 37th annual Health Sciences Research Day. The one day event featured many different ...

Qure N.V. (NASDAQ:QURE) shares plunged 75% on Monday after the biotech company announced a major regulatory setback for its ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its ...

WITH his cloth cap and tic-tac hand gestures, 80-year-old bookie Roger Barton is Romford dog track – after 50 years of ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaign TD is a chronic movement ...

THE friendship between a Yorkshire businesswoman Lyndsay Watterson, founder of Neo Walk, and the first disabled Miss Great Britain has led to ...